Konstantinidis IT, et al. - Authors sought to assess the role of the modified frailty index (MFI) in predicting outcomes for patients undergoing cytoreduction (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Findings suggested that frailty was a strong predictor of major grade 4 morbidity and mortality after CRS/HIPEC. Thereby suggesting severe frailty as a relative contraindication to CRS/HIPEC. They suggested considering frailty correlates as a selection factor in the evaluation of all candidates for CRS/HIPEC.